Sanofi (NASDAQ:SNY) Upgraded at Sanford C. Bernstein

Sanford C. Bernstein upgraded shares of Sanofi (NASDAQ:SNY) to a strong-buy rating in a research report sent to investors on Thursday,Zacks.com reports.

SNY has been the topic of a number of other reports. TD Cowen reiterated a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a report on Friday, January 16th. Wall Street Zen downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. Finally, Barclays lowered Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, Sanofi currently has an average rating of “Moderate Buy” and an average target price of $61.50.

Sanofi Stock Performance

NASDAQ:SNY opened at $44.60 on Thursday. The stock has a market cap of $108.78 billion, a P/E ratio of 12.39, a PEG ratio of 1.15 and a beta of 0.45. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The business’s 50-day moving average price is $46.46 and its two-hundred day moving average price is $48.04. Sanofi has a twelve month low of $43.32 and a twelve month high of $57.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Flagship Harbor Advisors LLC bought a new position in shares of Sanofi during the fourth quarter valued at approximately $25,000. Financial Consulate Inc. bought a new position in Sanofi in the 3rd quarter worth $26,000. Measured Wealth Private Client Group LLC purchased a new stake in shares of Sanofi in the 3rd quarter worth about $29,000. Palisade Asset Management LLC bought a new stake in shares of Sanofi during the 3rd quarter valued at about $30,000. Finally, First Horizon Corp purchased a new position in shares of Sanofi during the third quarter valued at about $33,000. Institutional investors own 14.03% of the company’s stock.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.